Biblio

Author Title [ Type

] Year

Filters: Author is Nishida, Tetsuya [Clear All Filters]

Journal Article

Yanagisawa R, Koyama H, Yakushijin K, Uchida N, Jinguji A, Takeda W, Nishida T, Tanaka M, Eto T, Ohigashi H, et al. Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023.

Takagi E, Terakura S, Fujigaki H, Okamoto A, Miyao K, Sawa M, Morishita T, Goto T, Ozawa Y, Nishida T, et al. Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts. Int J Hematol. 2023.

Imahashi N, Ohashi H, Terakura S, Miyao K, Sakemura R, Kato T, Sawa M, Yokohata E, Kurahashi S, Ozawa Y, et al. Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse. Ann Hematol. 2015.

Konuma T, Yamasaki S, Ishiyama K, Mizuno S, Hayashi H, Uchida N, Shimabukuro M, Tanaka M, Kuriyama T, Onizuka M, et al. Comparison of allogeneic transplant outcomes between matched sibling donors and alternative donors in patients over 50 years of age with acute myeloid leukemia: 8/8 allele-matched unrelated donors and unrelated cord blood provide better leukemia-free surv. Transplant Cell Ther. 2023.

Imahashi N, Kurita N, Konuma T, Takahashi S, Nishida T, Tanaka M, Nakamae H, Kawakita T, Ota S, Doki N, et al. Effect of conditioning regimens and GVHD prophylaxis on the outcomes of umbilical cord blood transplantation performed with cyclophosphamide/total-body irradiation-based regimens. Transplant Cell Ther. 2023.

Yokoyama H, Takenaka K, Nishida T, Seo S, Shinohara A, Uchida N, Tanaka M, Takahashi S, Onizuka M, Kozai Y, et al. Favorable effect of cytomegalovirus reactivation on outcomes in cord blood transplantation and its differences among disease risk or types. Biol Blood Marrow Transplant. 2020.

Jo T, Ueda T, Akahoshi Y, Kondo T, Uchida N, Tanaka M, Nakamae H, Doki N, Ota S, Sawa M, et al. First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia. Br J Haematol. 2024.

Shimomura Y, Kitamura T, Konuma T, Nakaya Y, Doki N, Sawa M, Nakamae H, Eto T, Nishida T, Ohigashi H, et al. Hematopoietic stem cell transplantation from haploidentical offspring donors using post-transplant cyclophosphamide versus human leukocyte antigen-matched siblings in older patients with myelodysplastic syndrome. Am J Hematol. 2023.

Kaito S, Nakajima Y, Hara K, Toya T, Nishida T, Uchida N, Mukae J, Fukuda T, Ozawa Y, Tanaka M, et al. Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. Blood Adv. 2020;4(6):1051-1061.

Nakaya Y, Koh H, Konuma T, Shimomura Y, Ishiyama K, Itonaga H, Hino M, Doki N, Nishida T, Ohigashi H, et al. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome. Transplant Cell Ther. 2023.

Yamamoto R, Hiramoto N, Fujimoto A, Yamazaki H, Mori T, Uchida N, Doki N, Kato J, Nishikubo M, Kako S, et al. Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024.

Konishi T, Matsuda K, Itonaga H, Doki N, Nishida T, Matsuoka K-I, Ikeda T, Kanda Y, Fukuda T, Kanda J, et al. Impact of Early Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation on Relapse in Patients with Myelodysplastic Syndrome: A Nationwide Retrospective Study from Adult Myelodysplastic Syndrome Working Group of the JSTCT. Transplant Cell Ther. 2024.

Hayashi H, Iwasaki M, Nakasone H, Tanoshima R, Shimabukuro M, Takeda W, Nishida T, Kako S, Fujiwara S-I, Katayama Y, et al. Impact of stem cell selection between bone marrow and peripheral blood stem cells for unrelated hematopoietic stem cell transplantation for hematologic malignancies: on behalf of the Donor/Source Working Group of the Japanese Society for Transplantation a. Cytotherapy. 2023.

Shimomura Y, Komukai S, Kitamura T, Tachibana T, Kurosawa S, Itonaga H, Tsukamoto S, Doki N, Katayama Y, Ito A, et al. The prognosis and risk factors for patients with complex karyotype myelodysplastic syndrome undergoing allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2023.

Itonaga H, Miyazaki Y, Fujioka M, Aoki J, Doki N, Nishida T, Fukuda T, Uchida N, Ueda Y, Uehara Y, et al. Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy. Bone Marrow Transplant. 2024.

Watanabe M, Konuma T, Imahashi N, Terakura S, Seo S, Morishima S, Uchida N, Doki N, Tanaka M, Nishida T, et al. Scoring system for optimal cord blood unit selection for single cord blood transplantation. Cytotherapy. 2023.

Imahashi N, Nishida T, Goto T, Terakura S, Watanabe K, Hanajiri R, Sakemura R, Imai M, Kiyoi H, Naoe T, et al. Simple and Efficient Generation of Virus-specific T Cells for Adoptive Therapy Using Anti-4-1BB Antibody. J Immunother. 2015;38(2):62-70.